After receiving the CE mark, Biotronik has launched its next-generation injectable cardiac monitor (ICM)—BioMonitor III—onto the European market. A press release reports that the novel device is designed to help patients with irregular heart rhythms by documenting suspected arrhythmia or unexplained syncope with increased clarity. Aiming to improve the accuracy of arrhythmia detection and diagnosis, the press release adds, the new ICM offers increased signal quality.
According to the press release, BioMonitor III’s “unique” BIOvector is designed to deliver high definition signals. The goal is for the high-signal amplitudes and visibility of the p-waves to make it easier for the physician to confidently evaluate arrhythmias. Furthermore, the new ICM is 60% smaller than its predecessor—BioMonitor 2—and comes ready to inject, with the device pre-assembled in a one-piece injection tool. To optimise patient comfort, BioMonitor III seeks to offer a very small size and flexible sensing antenna. The device is injected under the skin with a very small incision, facilitating in-office treatments.
The system works with Biotronik’s fully automated, “plug in and go” Home Monitoring. Due to automatic pairing, initialisation and data transmission no active patient involvement is required. The new product also features “Intelligent Memory Management”, which is designed to prevent the overwriting of clinically relevant episodes. Thus, no relevant information is missed.
Paul Goul (St Andrew’s War Memorial Hospital, Brisbane, Australia) says: “What I like about BioMonitor III is the ease of use and the high signal fidelity. This coupled with the automatic Home Monitoring, provide an excellent resource to establish a rhythm symptom correlation or to detect occult arrhythmias in my patients.”
Alexander Uhl, senior vice president corporate marketing at Biotronik, says: “We developed BioMonitor III to bring an injectable diagnostic solution with clear signal quality to the market. Working with an ICM should be easy, efficient and in-office-friendly—Biomonitor III is exactly that. With all its features, our new monitor reliably provides physicians with the needed information in high quality on the patient’s condition to avoid health risks associated with arrhythmia.”
